Announces Resignation and Appointment of Directors | 28-Jun-2023 | 09:04 | RNS |
Published in the New England Journal of Medicine | 08-Jun-2023 | 07:00 | RNS |
Burning Rock Reports 1st Quarter Financial Results | 30-May-2023 | 07:00 | RNS |
BNR Schedules Q1 Earnings Release on May 30, 2023 | 27-Apr-2023 | 07:00 | RNS |
BNR Publishes 2022 Annual Report on Form 20-F | 21-Apr-2023 | 07:00 | RNS |
Burning Rock Reports Q4 and Full Year 2022 Results | 28-Mar-2023 | 07:00 | RNS |
BNR Schedules 22Q4 and Full Year ER on March 28 | 07-Mar-2023 | 08:31 | RNS |
An update on 2022 revenue guidance | 18-Jan-2023 | 07:00 | RNS |
BNR Received FDA Breakthrough Device Designation | 03-Jan-2023 | 14:53 | RNS |
Burning Rock Third Quarter 2022 Financial Results | 16-Nov-2022 | 07:00 | RNS |
Prospectus Supplement Filed with U.S. SEC | 08-Nov-2022 | 07:00 | RNS |
Admission to Trading on the London Stock Exchange | 01-Nov-2022 | 09:54 | RNS |
Currency | US Dollars |
Price | $ 0.00 |
Closing Price Change | $ 0.00 |
% Change | 0.00 % |
52 Week High | $0.00 |
52 Week Low | $0.00 |
Volume | 0 |
Time | Volume / Share Price |
0 @ $0.00 |
You are here: research